New Blood: Former Novartis Exec Transitions to Rubius Therapeutics
New Red-Blood-Cell-Derived Therapies Are Poised to Launch Rubius into the Spotlight.
Improving Human Health: The Promise of Epigenetics
A New Perspective for Genomic Research from Prof. Shankar Balsubramanian
Translating Innovation into Therapies
Antimicrobial Resistance and Drug Commercialization Were Key Topics at the Recent ON Helix Conference in Cambridge, U.K.
Literature Review: Dielectrophoresis to the Fore
Old Methodology Resurrected to Allow Inexpensive Label-Free Separation of Cell Populations
Bioethics of GM Humans
The Journal of the Royal Society of Medicine recently published two opposing viewpoints on the ethics of using gene-editing technology human embryos. One article, written by an actress who has a rare form of dwarfism, maintains that gene editing does not represent a benefit to healthcare. The other, written by an Oxford research fellow, makes the case that while gene editing is not without controversy it should be developed.
The first author makes the point that social inequality would increase between those who were and were not genetically modified. While the second author makes the distinction that gene editing embryos is about modifying life where it already existed versus artificial selection which chooses which embryo is allowed to continue developing.